CHI and Cancer Commons will present a plenary panel on Personalized Oncology at the Molecular Medicine Tri-Confernce in San Francisco

Plenary Keynotes

Wednesday, February 13
8:00 – 9:40 am

Personalized Oncology – Fulfilling the Promise for Today’s Patients

In honor of the 20th anniversary of the Molecular Medicine Tri-Conference, CHI and Cancer Commons will present a plenary panel on Personalized Oncology. Innovations such as NGS and The Cancer Genome Atlas have revealed that cancer comprises hundreds of distinct molecular diseases. Early clinical successes with targeted therapies suggest that cancer might one day be managed as a chronic disease using an evolving cocktail of drugs.Representing all five conference channels, Diagnostics, Therapeutics, Clinical, Informatics, and Cancer, a panel of experts will lead a highly interactive exploration of what it will take to realize this vision in the near future. Continue reading…


Science Exchange/Cancer Commons in BioWorld article

Patients Take the Lead in Clinical Whole Genome Sequencing

From the article by Catherine Shaffer:

“Elizabeth Iorns, a representative of Science Exchange, said many of its providers are CLIA certified, and that the group is planning to expand into clinical services in partnership with Cancer Commons, a nonprofit open science initiative working toward bringing next-generation genomics technologies to patients.”

Read the full article here.


Cancer Commons Featured in SF Business Times

Trial and error: Biotechs, patients, FDA search for faster, cheaper ways to develop drugs.

From the article by Ron Leuty:

“Take Marty Tenenbaum, a metastatic melanoma survivor who has led efforts to link patients, researchers and companies in an open-science initiative, called Cancer Commons. His thinking is the more that patients know clinical trial results — and, importantly, report their own — the faster patients will populate the right clinical trials that are right for them.”

Read more here.


Dr. Tenenbaum to speak at Personalized Medicine World Conference

Dr. Tenenbaum to speak at the Personalized Medicine World Conference on January 28, 2013.
The 5th Annual Personalized Medicine World Conference on January 28-29 in Silicon Valley, provides an opportunity to learn from and engage in dialogue to further the field of personalized medicine. PMWC 2013 will bring together CEOs, entrepreneurs, researchers, clinicians, regulators and payers to present the latest progress and next challenges for the implementation of personalized medicine within a framework to address the coverage barriers. Featuring the premier leaders in the field, the Conference offers an opportunity to share best practices and build on lessons learned.


Cancer Commons congratulates board member Dr. Peter Yu, Elected ASCO President for 2014-2015 Term

Cancer Commons congratulates our board member, Dr. Peter Yu, who has been elected ASCO’s President for the 2014-2015 term.  Dr. Yu will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2013.

“I am both honored and privileged by the opportunity to lead ASCO,” said Dr. Yu. “I have been fortunate to serve the Society for many years in a volunteer capacity, and in doing so, have developed a depth and breadth of knowledge and experience on issues that are important for the advancement of cancer science and care. As President of the Society, I look forward to working collaboratively with the membership, staff and Board of Directors to further advance the ASCO mission and vision.”

Read the ASCO press release here.


Cancer Commons Announces Participation on the Stand Up To Cancer West Coast Dream Team for Prostate Cancer

A multi-center “dream team’’ of scientists, led by UCSF, is embarking on a groundbreaking $10M initiative in personalized medicine, to overcome therapeutic resistance in patients with advanced prostate cancer. Cancer Commons is supporting the Team through collaboration with Ted Goldstein and Josh Stuart of UCSC on the development of Medbook, a “Facebook for Cancer,” which will connect the team’s scientists and clinicians in a “rapid learning community”.  Participants will be able to collaboratively analyze and discuss the data from refractory prostate cancer patients at all participating centers, to identify the molecular drivers of this disease and optimal interventions.  This knowledge will be continually tested and refined based on the latest laboratory and clinical findings.  Our vision is for every patient to be treated using the best and most up-to-date knowledge and to update that knowledge based on each patient’s response. Clinically actionable results will be rapidly disseminated through Medbook to affected patients and their physicians.

Learn more about this exciting initiative at: UCSF News Prostate Cancer Dream Team Gets 10 Million Grant 


Sarah Greene Speaks at Open Science Summit on Rapid Learning Community

Sarah Greene, Executive Director at Cancer Commons, speaks at the Open Science Summit in Mountain View, California on Saturday, October 20, 2012.   Ms. Greene discusses Cancer Commons Rapid Learning Community.

To view: Patient Empowerment and the Future of Clinical Trials  Ms. Greene’s session begins at 27:02 mark.


Dr. Tenenbaum Speaks at the Institute of Medicine’s Sharing Clinical Research Data Workshop – Proposes Rapid Learning Inititative to Jump-Start Data Sharing in Cancer

Dr. Tenenbaum speaks at the Institute of Medicine’s Sharing Clinical Research Data:  An Institute of Medicine Workshop, October 4-5, 2012 at the National Academy of Sciences Building in Washington DC

Background:
Pharmaceutical companies, academic institutions, advocacy organizations, and government agencies such as FDA and NIH have large quantities of clinical research data. Increased data sharing could facilitate scientific and public health advances, among other potential benefits to patients and society. Much of this information, however, is not transparent or shared beyond the data owner. More specifically, study results are not always published and where results are published, they typically only include summary-level data; participant-level data is privately held and rarely shared or revealed publicly.
This workshop will explore the benefits of and barriers to the sharing of clinical research data and will help identify strategies for enhancing sharing both within and across sectors. To facilitate identification of key issues and potential solutions, the workshop will focus on data resulting from preplanned interventional studies of human subjects. While recognizing the importance of other data sources such as observational studies and electronic health records, this focus was selected to encourage concrete problem-solving discussions over the course of a day-and-a-half meeting. Models and projects that involve sharing other types of data will be considered during the workshop to the extent that these models provide lessons and best practices applicable to sharing preplanned interventional clinical research data.

The workshop is being jointly organized by the Institute of Medicine’s Forum on Drug Discovery, Development, and Translation; Forum on Neuroscience and Nervous System Disorders; National Cancer Policy Forum; and Roundtable on Translating Genomic-Based Research for Health.

Meeting Objectives:

  • Examine the benefits of sharing of clinical research data, and specifically clinical trial data, from all sectors and among these sectors, including, for example:
  • Benefits to the research and development enterprise
  • Benefits to the analysis of safety and efficacy
  • Identify barriers and challenges to sharing clinical research data
  • Explore strategies to address these barriers and challenges, including identifying priority actions
  • and “low-hanging fruit” opportunities
  • Discuss strategies for using these potentially large data sets to facilitate scientific and public
  • health advances.October 4-5, 2012 at the National Academy of Sciences in Washington, DC.

Additional information can be found at the Institute of Medicine’s Website


Dr. Tenenbaum, Speaks at Translational Pre-Clinical Oncology Consortium (TransPoc) Conference

Dr. Tenenbaum speaks at the Translational Pre-Clinical Oncology Consortium (TransPoC) Conference in Cambridge, MA on Personalized Therapy and Patient‐Centric Paradigm for Translational Medicine that tightly integrates clinical and pre-clinical research.